Author name: mary

HistoIndex’s AI-based Digital Pathology Platform: A Validated Quantification Tool Recommended in the Guidelines for the Prevention and Treatment of Chronic Hepatitis B in China   SINGAPORE, May 24, 2020 – Singapore medtech company HistoIndex’s AI-based stain-free digital pathology platform has long been established as a suitable tool for global clinical guidelines that outline the assessment, prevention …

HistoIndex’s AI-based Digital Pathology Platform: A Validated Quantification Tool Recommended in the Guidelines for the Prevention and Treatment of Chronic Hepatitis B in China Read More »

qFIBS Demonstrates Suitability for Nonalcoholic Steatohepatitis (NASH) Assessment in Clinical Trials and Patient Care with Full Quantification of All Crucial Histopathological Features   SINGAPORE, Nov. 9, 2019 – qFIBS, a novel automated algorithm developed by HistoIndex, has been shown to accurately distinguish different grades and stages of histological NASH features with a continuous measurement approach. This …

qFIBS Demonstrates Suitability for Nonalcoholic Steatohepatitis (NASH) Assessment in Clinical Trials and Patient Care with Full Quantification of All Histopathological Features Read More »

HistoIndex Announces Global Partnerships To Expand AI-Based Digital Pathology Platform As A Drug Discovery Tool In Preclinical Studies For Nonalcoholic Steatohepatitis (NASH)   The Singapore-based company has fostered partnerships with pharmaceutical and biotech companies, Contract Research Organizations (CROs), academia and government-linked research institutes in empowering NASH drug discovery. SINGAPORE, Oct. 26, 2019 – HistoIndex announces the …

HistoIndex Announces Global Partnerships to Expand AI-Based Digital Pathology Platform as a Drug Discovery Tool in Preclinical Studies for Nonalcoholic Steatohepatitis (NASH) Read More »

LITMUS – Progress towards diagnosing and better treating liver disease   A pioneering European research project, designed to develop new diagnostic tests to assess patients with Non-Alcoholic Fatty Liver Disease (NAFLD) has expanded giving access to more patients. Incorporating several new partners also enables access to even more state-of-the-art technologies.   Liver Investigation: Testing Marker …

LITMUS – Progress towards diagnosing and better treating liver disease Read More »

HistoIndex and ILBS Launch Centre of Excellence in New Delhi for Advanced Diagnostics and Clinical Research on Nonalcoholic Steatohepatitis (NASH)   [Picture by Enterprise Singapore. From Left] Professor Balram Bhargava, Director General, Indian Council of Medical Research; Secretary, Department of Health Research, India, Mr Lim Thuan Kuan, High Commissioner of the Republic of Singapore in …

HistoIndex and ILBS Launch Centre of Excellence in New Delhi for Advanced Diagnostics and Clinical Research on Nonalcoholic Steatohepatitis (NASH) Read More »

HistoIndex’s Second Harmonic Generation (SHG) Technology: A Potentially Important Tool Used In Madrigal’s Phase 2 Nonalcoholic Steatohepatitis (NASH) Clinical Trial   SINGAPORE, Dec. 23, 2018 – HistoIndex’s AI-based SHG technology has the potential to yield important results from NASH clinical trials.  HistoIndex’s SHG technology was featured in Madrigal Pharmaceuticals’ Presidential Plenary presentation during AASLD’s The Liver Meeting® 2018, for its presentation …

HistoIndex’s Second Harmonic Generation (SHG) Technology: A Potentially Important Tool Used In Madrigal’s Phase 2 Nonalcoholic Steatohepatitis (NASH) Clinical Trial Read More »

A Worldwide Effort to Defeat Nonalcoholic Steatohepatitis (NASH)   The silent disease known as NASH is on the rise worldwide. Therefore, stronger public awareness is needed in detecting NASH and fibrosis early in order to facilitate timely and quality medical intervention. With the liver biopsy as the current gold standard for NASH diagnosis, HistoIndex can …

A Worldwide Effort to Defeat Nonalcoholic Steatohepatitis (NASH) Read More »

HistoIndex and CymaBay Therapeutics Team up to Advance NASH Drug Development   Histoindex Pte. Ltd., with the world’s first stain-free Genesis®200 multiphoton digital pathology system, is collaborating with CymaBay Therapeutics, Inc. to evaluate the efficacy of seladelpar in a randomized, double-blind, placebo-controlled, multi-center Phase 2b study of 175 subjects with biopsy-confirmed Nonalcoholic Steatohepatitis (NASH). Genesis®200’s novel imaging technology encompasses …

HistoIndex and CymaBay Therapeutics Team Up to Advance NASH Drug Development Read More »